Genome-wide CRISPR/Cas9 screens reveal shared and cell-specific mechanisms of resistance to SHP2 inhibition.

"all sequence data (rnaseq genome-wide and focused crispr screens) are available in the gene expression omnibus database under accession no gse218491 ."

"Disclosures: N.E. Sanjana reported personal fees from Vertex and Qiagen outside the submitted work and has equity in and is a co-founder and advisor to OverT Bio. B.G. Neel reported grants from the National Cancer Institute during the conduct of the study and personal fees from Navire Pharmaceuticals, Northern Biologics, Ltd, Lighthorse Pharmaceuticals, Aethon Therapeutics, Arvinas, Recursion Pharma, and MPM Capital outside the submitted work. No other disclosures were reported."

"We also thank the PCC Genome Technology Center, Applied Bioinformatics Laboratory, and Immune Monitoring Laboratory shared resources, funded by National Institutes of Health (NIH) National Cancer Institute (NCI) grant P30 CA016087. This work was supported by NIH-NCI grants CA49152 and CA244896 to B.G. Neel and NIH National Human Genome Research Institute grant HG010099 to N.E. Sanjana."